Chen et al. have developed a preclinical platform that enables the reprogramming of locoregional macrophages and microglia in situ with CD133-directed chimeric antigen receptors, which leads to the phagocytosis and removal of residual glioma stem cells after tumour debulking.
更多
查看译文
关键词
Cancer immunotherapy,Cancer therapy,CNS cancer,Biomedicine,general,Cancer Research
原文链接
分享
引用
